Annual Meetings, Clinical Data Presentation, Acquisitions, Agreements, and Date Extensions - Analyst Notes on Omnicare, Auxilium, Covance, Ophthotech and Keryx

NEW YORK, May 27, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Omnicare Inc. (NYSE: OCR), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Covance Inc. (NYSE: CVD), Ophthotech Corporation (NASDAQ: OPTH) and Keryx Biopharmaceuticals Inc. (NASDAQ: KERX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2974-100free.

--
Omnicare Inc. Analyst Notes
On May 22, 2014, Omnicare Inc. (Omnicare) held its Annual Meeting of Stockholders in which nine directors were elected by stockholders to serve at the Company's Board of Directors until next year's Annual Meeting or until their respective successors are duly elected and qualified. Stockholders also approved the compensation paid to the Company's named executive officers. During the meeting, the Company's stockholders further ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for Omnicare in 2014, while also approving the adoption of the 2014 Stock and Incentive Plan and re-approving the performance criteria under the Annual Incentive Plan for Senior Executive Officers. The full analyst notes on Omnicare are available to download free of charge at:

http://www.analystsreview.com/2974-OCR-27May2014.pdf

--
Auxilium Pharmaceuticals Inc. Analyst Notes
On May 19, 2014, Auxilium Pharmaceuticals Inc. (Auxilium) announced the presentation of new analyses of data from its clinical program and pivotal IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the Phase 3 studies dealing with the evaluation of XIAFLEX® for the treatment of Peyronie's disease (PD). The said data were presented at the American Urological Association Meeting held in Orlando, Florida on May 16-21, 2014. Highlights of the presentation include findings that 75% of men with PD treated with XIAFLEX in the studies reported a 25% or greater improvement in penile curvature deformity. The presentation also highlighted that there was no detectable effect of XIAFLEX on the structure of blood vessels, nerves and fibroblasts at any dose evaluated. The full analyst notes on Auxilium are available to download free of charge at:

http://www.analystsreview.com/2974-AUXL-27May2014.pdf

--
Covance Inc. Analyst Notes
On May 19, 2014, Covance Inc. (Covance) announced that it has acquired Medaxial, a London-based value communication consultancy, providing clients an integrated approach to market access strategy, health economic modeling, and data dissemination services. The Company stated that after this acquisition, its market access services are expected to be better positioned to serve clients worldwide. Commenting on the acquisition, Vice President and General Manager, Covance Market Access, Marc Ginsky said, "This acquisition will enhance Covance's ability to bring value communication solutions to our clients, beginning early in drug development and continuing through regulatory approval, reimbursement, and commercial success". The full analyst notes on Covance are available to download free of charge at:

http://www.analystsreview.com/2974-CVD-27May2014.pdf

--
Ophthotech Corporation Analyst Notes
On May 19, 2014, Ophthotech Corporation (Ophthotech) announced an ex-US licensing and commercialization agreement with Novartis Pharmaceuticals focused on the treatment of wet age-related macular degeneration (AMD). The agreement grants Novartis exclusive rights to commercialize Ophthotech's Fovista® in markets outside the United States while Ophthotech retains sole rights to commercialize Fovista® in the United States. According to the Company, potential payments to Ophthotech under the agreement could be over $1 billion in upfront and milestone payments, excluding future royalties. Ophthotech stated that this collaboration is in line with the Fovista development strategy to remain agnostic with respect to the choice of the anti-VEGF agent administered in combination with Fovista. Ophthotech's CEO and Chairman David R. Guyer, M.D. said, "This agreement represents an important achievement for the Company as we continue to execute on a strategy to deliver science-driven retinal products and offer physicians multiple treatment options to improve patient outcome." The full analyst notes on Ophthotech are available to download free of charge at:

http://www.analystsreview.com/2974-OPTH-27May2014.pdf

--
Keryx Biopharmaceuticals Inc. Analyst Notes
On May 22, 2014, Keryx Biopharmaceuticals Inc. (Keryx) announced that the U.S. Food and Drug Administration (FDA) has extended the initial Prescription Drug User Fee Act (PDUFA) goal date to September 7, 2014 for its review of the Company's New Drug Application (NDA) seeking marketing approval of ZerenexTM (ferric citrate). The Company stated that the FDA extended the goal date by three months to provide time to fully review the submission recently made by the Company in response to a Chemistry, Manufacturing and Controls (CMC) section information request from the FDA. Commenting on the FDA extension, Keryx CEO Ron Bentsur said, "We believe that we have sufficiently responded to the questions that we have received to date and will work with the FDA to answer any additional questions that they may have in order to complete their review of the Zerenex NDA". The full analyst notes on Keryx are available to download free of charge at:

http://www.analystsreview.com/2974-KERX-27May2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review